We're working on profiling this company soon. Let us know you're interested by sending us a request here »
We're working hard to bring you this company's profile. Register here to get an alert as soon we're done.
In the meantime, if you are interested in participating in placements on this stock click "Follow" on the toolbar above.
Botanix has FDA approval for its treatment for hyperhidrosis, or excessive sweating Sufferers have...
Read ArticleTrue to its history of reinvention and repurposing, Pharmaust will be renamed Neurizon Therapeutics...
Read ArticleAlive and Kicking is renowned biotech journo Tim Boreham’s new daily wrap covering morning movers an...
Read ArticleLooking to add a few small-cap ASX healthcare stocks to your portfolio with some outsized growth pot...
Read ArticleASX healthcare shares are often touted here on the Australian share market. We are home to some of t...
Read ArticleFor biotech investors, the news of an approval by the US FDA is a genuinely exciting milestone. The...
Read ArticleThe ASX200 reversed its trend to end the week in the green, up 0.35% Nearly all sectors made gain...
Read ArticleIn afternoon trade, the S&P/ASX 200 Index (ASX: XJO) is on course to end the week with a small...
Read ArticleBotanix Pharmaceuticals Ltd (ASX: BOT) shares are ending the week on a positive note. In morning tra...
Read ArticleIt’s looking like another red day on the market, with the ASX flattish around intraday trades. Se...
Read ArticleBotanix Pharmaceuticals (ASX:BOT) on Thursday described itself as having transitioned from a develop...
Read ArticleControl Bionics’s shares surge after TGA approval Control Bionics (ASX:CBL) surged by 51% this morni...
Read ArticleThe Botanix Pharmaceuticals Ltd (ASX: BOT) share price will be one to watch closely this week. That'...
Read ArticleClinical dermatology company Botanix Pharmaceuticals (ASX:BOT) has announced that the US FDA...
Read ArticleASX closes lower, but Energy sector blinks green Uranium mining stocks surged on Peter Dutton’s nuc...
Read ArticleThe All Ordinaries Index (ASX: XAO) is up 0.1% in morning trade today, but this ASX All Ords stock...
Read ArticleFDA panel rejects MDMA for PTSD treatment, citing safety and data concerns Advocates argue MDMA’s b...
Read ArticleThe S&P/ASX 200 Index (ASX: XJO) is having another disappointing session. In afternoon trade,...
Read ArticleClinical dermatology company, Botanix Pharmaceuticals (ASX:BOT) has submitted the last label materia...
Read ArticleASX biotech shares have been showing significant signs of momentum lately. Exciting clinical trial r...
Read ArticleImricor has two upcoming pivotal trials and is looking to transform cardiac ablation procedures Bo...
Read Article“Your Stock Request” is a weekly video where we analyse share price charts for stocks on the Austral...
Read ArticleWith a few notable exceptions, ASX cannabis shares widely underperformed again over the last year. T...
Read ArticleWhere are we in terms of US legalisation of cannabis? What about the current legal landscape for ca...
Read ArticleMomentum investing involves taking advantage of, and making profits from, upward trends in a stock....
Read Article“Your Stock Request” is a weekly video where we analyse share price charts for stocks on the Austral...
Read ArticleBotanix Pharmaceuticals (ASX: BOT) Finishes its $13.5 million placement to accelerate its US commerc...
Read ArticleTwo ASX cannabis shares aren't joining in the broader market rally today. During the Tuesday lunch...
Read ArticleASX health sector falls in line with broader markets on macroeconomic factors and global geopolitic...
Read ArticleL’Oréal to take minority stake in Chinese startup Shinehigh Innovation Shinehigh is developing supr...
Read ArticleThe ASX200 closed the day down half a per cent. As far as the sector performances, healthcare wa...
Read ArticleBotanix Pharmaceuticals’ (BOT) application to use sofpironium bromide gel to treat primary axillary...
Read ArticleIn afternoon trade, the S&P/ASX 200 Index (ASX: XJO) is on course to record a disappointing de...
Read ArticleUS FDA requested Botanix to change its instructions paper Antisense says ATL1102 could be effective...
Read ArticleStockhead’s Top 10 at shortly-before-11-ish, written through a red haze of blazing, sweary anger thi...
Read ArticleThe Botanix Pharmaceuticals Ltd (ASX: BOT) share price has returned from its trading halt and crash...
Read ArticleASX health sector falls in line with broader markets as macroeconomic factors continue to create un...
Read ArticleCannabis stocks are rebounding, catching short sellers off guard Next signpost for weed investors i...
Read ArticleThe Botanix Pharmaceuticals Ltd (ASX: BOT) share price hit a 52-week high of 21 cents this morning...
Read ArticleEarnings reports dominated headlines in August Despite solid results from ASX healthcare giants, th...
Read ArticleAustralian biotech has attracted US investments in the last five years Among ASX stocks to get fund...
Read ArticleNew chief executive has experience executing clinical studies Dr Thurn was formerly part of the TG...
Read ArticlePharmAust (PAA) appoints Dr Michael Thurn as its newest CEO, effective September 1 The company re...
Read ArticleBotanix Pharmaceuticals (ASX: BOT) has announced that its chief operating officer has been a...
Read ArticleBotanix Pharmaceuticals (BOT) appoints Dr Howie McKibbon as its newest CEO Dr McKibbon was previo...
Read ArticleFutures predict the ASX will open lower to finish the week, triggered by tech shares losing momentum...
Read ArticleLocal shares set to open sharply lower on Friday Wall Street tumbled by over 1pc overnight as tech...
Read ArticleMastercard says no to weed transactions New York is where weed is happening Jeremy Buckingham pulls...
Read Article“Your Stock Request” is a weekly video where we analyse share price charts for stocks on the Austral...
Read ArticleBotanix Pharmaceuticals (BOT) completes a $12.5 million placement and executes a buyout agreement fo...
Read ArticleBotanix Pharmaceuticals has secured commitments from investors to raise up to $12.5 million via an i...
Read ArticleBotanix Pharmaceuticals (BOT) raises $12.5 million through an institutional placement Funds will...
Read ArticleClinical validation study confirms efficacy of INOVIQ’s SubB2M/CA15-3 test for breast cancer Ramsa...
Read ArticleThe weed industry has slumped as it faces several headwinds But new data suggests the industry will...
Read ArticleThe infectious diseases space is one area that could be interesting for ethical investors An ASX co...
Read ArticleStockhead’s In-Case-You-Missed-It highlights some strongest performing ASX stocks that might have sl...
Read ArticleOncoSil gets Ethics committee approval Starpharma’s nasal spray VIRALEZE granted approval in Malay...
Read ArticleThe market shows that biotechs are making a gradual comeback in 2023 What are some of the catalysts...
Read ArticleA handful of ASX biotechs are entering their crucial stages of development Promising outlooks for P...
Read ArticleClinical dermatology company Botanix Pharmaceuticals (ASX:BOT) has secured commitments to ra...
Read ArticleASX 200 benchmark closes 0.5% higher, thanks to Energy surge. XTX All Technology index has the bat...
Read ArticleBotanix Pharmaceuticals’ (BOT) lead product, Sofpironium Bromide, passes an FDA mid-cycle review...
Read ArticleBotanix Pharmaceuticals chief operating officer Dr Howie McKibbon believes Aussie Investors are comf...
Read ArticleThe ASX 200 was unchanged The ASX XEC slips 0.38% 8 out of 11 sectors were higher lead by Informa...
Read ArticleThe co-founder of Botanix Pharmaceuticals says early interest from big industry players like Pfizer...
Read ArticleTim Boreham is one of Australia’s best-known small-cap share analysts and business journalists. He h...
Read ArticleBotanix Pharmaceuticals (BOT) receives confirmation from the US FDA that its new drug application (N...
Read ArticleBotanix Pharmaceuticals (BOT) has raised $5.96 million through a placement and share purchase plan (...
Read ArticleTwo more US states join the 19 that already allow legal recreational cannabis use ECS Botanics’ Vic...
Read ArticleBotanix Pharmaceuticals (BOT) is raising up to $8 million through a private placement and a share pu...
Read ArticleNuheara secures FDA over-the-counter approval for its new affordable hearing aid Nitro Software rej...
Read ArticleAussie market delivers a rock-solid mediocre effort Koba Resources hits the jackpot by hammering so...
Read ArticleBotanix Pharmaceuticals’ (BOT) Chief Commercial Officer (CCO) is promoted to Chief Operating Officer...
Read ArticleBotanix Pharmaceuticals (BOT) receives positive data from its phase 1b/2 papulopustular rosacea clin...
Read ArticleClinical dermatology company Botanix Pharmaceuticals (ASX:BOT) has announced what it describ...
Read ArticleASX 200 ends flat as Small caps s wee bit lower OLL investment sparks share price surge We’re p...
Read ArticleIt is hump day, which the ASX 200 benchmark celebrated with a series of increasingly erratic and – d...
Read ArticleClinical-stage dermatology Botanix Pharmaceuticals (ASX:BOT) has submitted a New Drug Applic...
Read ArticleBotanix Pharmaceuticals (BOT) submits a new drug application (NDA) to the US FDA for the use of its...
Read ArticleBotanix submits NDA to the US FDA Pharmaxis reports on latest clinical trials PainChek to expand to...
Read ArticleClinical dermatology company Botanix Pharmaceuticals (ASX:BOT) has closed the first tranche...
Read ArticleBotanix Pharmaceuticals (BOT) is tapping investors for $7.5 million via a share placementThe company...
Read ArticleSmall caps burn rest of field. Again. Up 1.8% ASX 200 dips. Again DM1 jumps 75% over two sessions...
Read ArticleBotanix Pharmaceuticals, a listed developer of treatments for skin infections and diseases, was pitc...
Read ArticleBotanix Pharmaceuticals (BOT) accelerates the submission of a New Drug Approval (NDA) for its Sofpi...
Read ArticleBotanix’s FDA submission gets accelerated Release extends contract with Medgate to use the ResAppDx...
Read ArticleClinical dermatology company Botanix Pharmaceuticals (ASX: BOT) is preparing to submit a new drug ap...
Read ArticleClinical dermatology company Botanix Pharmaceuticals (ASX:BOT) has announced the timing of t...
Read ArticleAvita Medical makes spray on skin for burns and soft tissue injuries HITIQ’s concussion tech is pop...
Read ArticleBotanix Pharmaceuticals (ASX: BOT) has provided the market with an update on its progress in transfo...
Read ArticleHealthcare and life sciences expert Scott Power – a senior analyst with Morgans Financial for 24 yea...
Read ArticleActor and cannabis farmer Jim Belushi is headlining the Grow Up Conference and Expo next month Fran...
Read ArticleBotanix Pharmaceuticals (ASX:BOT) has announced the acquisition of a novel dermatology asset...
Read ArticleBotanix Pharmaceuticals (BOT) acquires Sofpironium Bromide gel from NASDAQ listed company Brickell...
Read ArticleShares in Perth dermatology company Botanix Pharmaceuticals have surged after it announced the acqui...
Read ArticleBotanix Pharmaceuticals (ASX: BOT) has acquired novel dermatology asset Sofpironium Bromide gel 15%...
Read ArticleThe interest rate rise came and the markets fell, then turned a corner. The question now is — will t...
Read ArticleBotanix Pharmaceuticals (BOT) is granted Qualified Infectious Disease Product (QIDP) status for its...
Read ArticleASX to rise after falling for the last three days LNG price surges after Russian cuts off supply to...
Read ArticleClinical dermatology company Botanix Pharmaceuticals (ASX:BOT) has confirmed upcoming presen...
Read ArticleHighlights The Australian healthcare sector includes companies engaged in biotechnology and rese...
Read ArticleASX Emerging Companies (XEC) index has closed 1.5% on Tuesday Index now over 10% the better since F...
Read ArticleShareCafeBotanix Pharmaceuticals (ASX: BOT) – Webinar Presentation Matt Callahan – Executive Direct...
Read ArticleShareCafeWebinar Recap – BOT, TZL & SLH Catch up on the full webinar with presentations from Bo...
Read ArticleBotanix Pharmaceuticals (BOT) shares its half yearly report and highlights its dermatology program...
Read ArticleBotanix Pharmaceuticals (BOT) has continued progressing multiple clinical programs over the Septemb...
Read ArticleFNArena will be updating Special Editions of this Report in September dedicated to the August Report...
Read ArticleMassachusetts based cannabis operator MariMed has just announced a joint collaboration with the lege...
Read ArticleAustralia has the potential to become the international gold standard for production of medicinal ma...
Read ArticleThe Botanix Pharmaceuticals Ltd (ASX: BOT) share price is dipping after the company released its la...
Read ArticleIt’s been a mixed two weeks for small-cap health companies, with 60 companies gaining ground and 52...
Read ArticleThe 2021 financial year was overall a very good one for ASX shares. The S&P/ASX 200 Index (ASX:...
Read ArticleThe Botanix Pharmaceuticals Ltd (ASX: BOT) share price was a very strong performer on Friday. The c...
Read ArticleSummary ASX-listed digital health company ResApp Health has recruited the first participant in i...
Read ArticleSummary Digital health player ResApp Health has entered into a non-exclusive distribution agreem...
Read ArticleASX biotechs Recce Pharmaceuticals (ASX:RCE) and Botanix Pharmaceuticals (ASX:BOT) have this morning...
Read ArticleSummary Medicinal cannabis player Botanix Pharmaceuticals Limited has provided a clinical develo...
Read ArticleAustralian clinical dermatology and antimicrobial company Botanix Pharmaceuticals (ASX:BOT)...
Read ArticleSummary Digital health behemoth ResMed has released its quarterly results for the March 2021 qua...
Read ArticleBotanix Pharmaceuticals (ASX:BOT) says research on the antimicrobial potential of CBD has be...
Read ArticleSummary Health House International has signed a non-exclusive distribution agreement with Dragon...
Read ArticleSource: photolona, Shutterstock Summary Australian Primary Hemp has signed another retail distr...
Read ArticleSource: janews, Shutterstock Summary ASX-listed cannabis player Botanix Pharmaceuticals has obt...
Read ArticleBotanix Pharmaceuticals (ASX:BOT) has announced it has received ethics approval for the BTX...
Read ArticleAustralian clinical-stage synthetic cannabinoid company Botanix Pharmaceuticals (ASX:BOT) ha...
Read ArticleBotanix Pharmaceuticals Ltd (ASX: BOT) shares are flat today following the company’s release of its...
Read ArticleBotanix Pharmaceuticals Ltd (ASX: BOT) shares are edging lower today despite the company reporting...
Read ArticleClinical stage synthetic cannabinoid company Botanix Pharmaceuticals (ASX:BOT) has published...
Read ArticleBotanix Pharmaceuticals (ASX:BOT) shares have soared after a small clinical trial backed the feasibi...
Read ArticleSummary Clinical stage synthetic cannabinoid player Botanix Pharmaceuticals has announced positi...
Read ArticleThe Botanix Pharmaceuticals Ltd (ASX: BOT) share price has returned from its trading halt with a ba...
Read ArticleBotanix Pharmaceuticals Ltd (ASX: BOT) shares are lifting off today after the company released its...
Read ArticleDespite a brief respite, the pot stock revival looks to still be on the cards. Botanix Pharmaceutica...
Read ArticleThe Botanix Pharmaceuticals Ltd (ASX: BOT) share price has been on fire on Wednesday. At one stage...
Read ArticleThe research article represents the culmination of research collaborations involving leading antimic...
Read ArticleBotanix Pharmaceuticals shares are on the rise after research showed that a synthetic cannabidiol fo...
Read ArticleThe pot stock resurgence isn’t slowing down yet! Cannabis companies are still going strong. With bio...
Read ArticleThe company is developing a pipeline of product candidates that leverage the antimicrobial propertie...
Read ArticleThe Botanix Pharmaceuticals Ltd (ASX: BOT) share price is trading higher today on news the company...
Read ArticleSummary Botanix Pharmaceuticals has completed BTX 1801 antimicrobial Phase 2a clinical study. T...
Read ArticleClinical stage cannabinoid company Botanix Pharmaceuticals (ASX:BOT) says it has successfull...
Read ArticleSummary Cannabinoid pharmaceutical player Botanix Pharmaceuticals has completed a pre-IND meeting...
Read ArticleThe Botanix Pharmaceuticals Ltd (ASX: BOT) share price is surging higher today after a positive ann...
Read ArticleThe Botanix Pharmaceuticals Ltd (ASX: BOT) share price is soaring higher today following the releas...
Read ArticleThe ASX is littered with lots of companies that show potential to become the next market darling. W...
Read ArticleASX cannabis stocks are continuing their victory lap following yesterday’s decision by the TGA to re...
Read ArticleClinical stage synthetic cannabinoid company Botanix Pharmaceuticals (ASX:BOT) says it has c...
Read ArticleThe Botanix Pharmaceuticals Ltd (ASX: BOT) share price surged more than 20% higher in early trade a...
Read ArticleSince the start of March, six clinical trials involving cannabis treatments around the world have be...
Read ArticleNorth American pot stocks are roaring back from lows in March but the same cannot be said for their...
Read ArticleThe cohort of 33 pot (and pot-adjacent) stocks tracked by Stockhead followed the broader market high...
Read ArticleInvestors have cheered confirmation the US FDA granted Botanix Pharmaceuticals' (ASX:BOT) fi...
Read ArticleAn additional news report on the recommendation, valuation, forecast and opinion changes for ASX-lis...
Read ArticleThis is a significant milestone for Botanix as BTX 1801 is the first cannabinoid-based program to re...
Read ArticleIn amidst the difficulties created by the COVID-19 pandemic, synthetic cannabinoid company Botanix P...
Read ArticleStockhead’s Top 10 at 10 highlights the best (and worst) performing ASX small caps in morning trade....
Read ArticleShort & Caught is Stockhead’s fortnightly recap of which ASX small cap stocks are heavily shorte...
Read ArticleStockhead’s Top 10 at 10 highlights the best (and worst) performing ASX small caps in morning trade....
Read ArticleAs fears surrounding the Coronavirus drive the markets down, one ASX-listed pot stock could triumph...
Read ArticleSynthetic cannabinoid company Botanix Pharmaceuticals (ASX: BOT) has unveiled the next phase of deve...
Read ArticleNeuren Pharmaceuticals (ASX:NEU) has been granted Rare Pediatric Disease (RPD) designation for its R...
Read ArticleAs market watchers would know, cannabis stocks globally have had a wild ride over the last three yea...
Read ArticleWith the health and life science sector being the ASX’s top performer last year, Western Australia i...
Read ArticleOnly one prescription for medical marijuana has been issued by a doctor in the Northern Territory, a...
Read ArticleFor an industry that’s projected to reach $US20 billion ($29 billion) by 2024 in the US, the cannabi...
Read ArticleClinical stage synthetic cannabinoid company Botanix Pharmaceuticals (ASX:BOT) says it is at...
Read ArticleLast year was a bear market for cannabis stocks globally. During 2019, the excitement that had foll...
Read ArticleOn Thursday the S&P/ASX 200 index started the year on a mildly positive note. The benchmark ind...
Read ArticleThis year was a difficult one for ASX cannabis shares as well as cannabis stocks globally with shar...
Read ArticleMarijuana is the hottest herb on the planet right now, but while investing in medical cannabis stock...
Read ArticleShort & Caught is Stockhead’s fortnightly recap of which ASX small cap stocks are heavily shorte...
Read ArticleEmerging or early-stage companies offer new investment opportunities to investors, and higher return...
Read ArticleCannabis industry player Elixinol Global (ASX:EXL) will take a $2.2m profit hit when it divests its...
Read ArticleShort & Caught is Stockhead’s fortnightly recap of which ASX small cap stocks are heavily shorte...
Read ArticleIn the year 2019, marijuana stocks were among the hot picks for investors, despite the general marke...
Read ArticleHealth care in Australia is the most diversified and dynamic sector and has the potential to generat...
Read ArticleIn this article we are discussing five ASX-listed health care stocks, Althea Group Holdings Limited...
Read ArticleCannabis has been progressively decriminalised around the world since the early 2000s, starting with...
Read ArticleCannabis Shares Valuing a cannabis company is becoming an increasingly difficult task. Lately, the c...
Read ArticleThere are no shortage of small cap health and biotech companies listed on the ASX — around 140 or so...
Read ArticleEach Monday, Stockhead recaps which stocks are most heavily in demand by investors — running hot. Th...
Read ArticleHere’s our fortnightly wrap of the major small cap health stock winners and losers. One small cap A...
Read ArticleIt’s been a year of highs and lows for cannabis shares. Marijuana shares were favourites of investo...
Read ArticleCannabis is a fast-growing industry with a dynamic and rapidly changing prospects, the medicinal can...
Read ArticleHealth care system of Australia is considered as one of the best, globally, as it delivers safe and...
Read ArticleHealth care sector is one of the popular sectors among investors, as it is one of the high yielding...
Read ArticlePn this day in 2001, Apple announced the release of the first iPod player. The iPod became the world...
Read ArticleAmidst the global market fickleness, competition and economic pressure, cannabis stocks stand out as...
Read ArticleListed cannabis stocks worldwide have pulled back from their highs lately, tainted by the vaping cr...
Read ArticleIn afternoon trade the S&P/ASX 200 index is on course to give back yesterday’s gains. At the ti...
Read ArticleBotanix Pharmaceuticals’ (ASX:BOT) shares have halved after its anti-acne drug failed its clinical t...
Read ArticleThe Elixinol Global Ltd (ASX: EXL) share price has come under significant selling pressure today af...
Read ArticleStockhead’s Top 10 at 10 highlights the best (and worst) performing ASX small caps in morning trade....
Read ArticleIt looks set to be a disappointing day of trade for the Botanix Pharmaceuticals Ltd (ASX: BOT) shar...
Read ArticleDrug development company Noxopharm (ASX: NOX) is growing more optimistic about the use of its Veyond...
Read ArticleIn the few short years since cannabis companies first floated on stock exchanges around the world, t...
Read ArticleClinical stage cannabinoid company Botanix Pharmaceuticals (ASX:BOT) has been awarded a new...
Read ArticleBiotech company Immutep (ASX:IMM) just got some positive results in a Phase I clinical trial for its...
Read ArticleShort & Caught is Stockhead’s fortnightly recap of which ASX small cap stocks are heavily shorte...
Read ArticleClinical stage Australian-based cannabinoid company Botanix Pharmaceuticals (ASX:BOT) says i...
Read ArticleIntroduction Investors seek high return on stocks and continue to invest in the stock market. Invest...
Read Article‘Pot stocks’ were making headlines in 2018. California, one of the world’s biggest economies and th...
Read ArticleDigital healthcare service has evolved as one of the fastest-growing industries in the modern era. I...
Read ArticleThe federal government has taken steps to cut red tape and speed up the granting of licences for Aus...
Read ArticleOpthea (ASX: OPT) shares have more than doubled this morning after announcing its Phase IIb clinical...
Read ArticleOn the cusp of what Botanix (ASX: BOT) is calling "one of the most significant chapters" in the deve...
Read ArticleThe Botanix Pharmaceuticals Ltd (ASX: BOT) share price is sagging today after the company made two...
Read ArticleBotanix Pharmaceuticals Limited (ASX: BOT) is an Australian-headquartered company, engaged in the de...
Read ArticleSkin treatments company Botanix Pharmaceuticals is in front of investors seeking a $40 million equit...
Read ArticleA new chain of medical cannabis clinics are set to roll out across Australia as part of a collaborat...
Read ArticleTaking the cannabis market to the next level, the US is now taking a closer look at the industry’s l...
Read ArticleThe biotechnology sector is one of those sectors that presents an incredible opportunity for huge re...
Read ArticleClinical stage cannabinoid company Botanix Pharmaceuticals (ASX:BOT) has announced new data...
Read ArticleThe below-mentioned healthcare stocks have provided significant returns in the last six months and h...
Read ArticleAlthough it has fought back from its lows, the S&P/ASX 200 index is still on course to start th...
Read ArticleThe Botanix Pharmaceuticals Ltd (ASX: BOT) share price has continued its impressive run and is up o...
Read ArticleAdherium (ASX: ADR) shares have risen 19 per cent this morning following news the asthma monitoring...
Read ArticleAs the cannabis sector gains momentum in Australia and given that medicinal cannabis was legalised i...
Read ArticleThe Australian share market may have dropped off a touch this week, but that hasn’t stopped a numbe...
Read ArticleDo you know that market enthusiasts believe that legalising cannabis would generate approximately $8...
Read ArticleI think it is fair to say that 2019 has been a very positive year for Australian investors. Since t...
Read ArticleClinical stage cannabinoid company Botanix Pharmaceuticals (ASX:BOT) has announced that Dr M...
Read ArticleThe two ASX traded companies BOT and NHS had updated investors about the latest developments in the...
Read ArticleIn another “world first” this week, Botanix Pharmaceuticals (ASX: BOT) has revealed its antimicrobia...
Read ArticleIn another “world first” this week, Botanix Pharmaceuticals (ASX: BOT) has revealed its antimicrobia...
Read ArticleThe Botanix Pharmaceuticals Ltd (ASX: BOT) share price has been a standout performer on the Australi...
Read ArticlePot stock Botanix (ASX:BOT) says one of its cannabis formulations kills superbugs — in animals and i...
Read ArticleAt the start of every trading day, it can be useful to know which stocks are humming out of the gate...
Read ArticleMedical dermatology company Botanix Pharmaceuticals (ASX:BOT) has updated investors on the f...
Read ArticleShares in grow-your-own-bone biotech Orthocell (ASX:OCC) are up after it proved, once again, that we...
Read ArticleThe market has continued its charge on Wednesday and is trading notably higher this morning. Two com...
Read ArticleNew results from a “world-first” study by Botanix Pharmaceuticals (ASX: BOT) has identified signific...
Read ArticleTwo stocks BOT and PM1 are on trading halts, pending their upcoming announcements on ASX. Let us hav...
Read ArticleHoney containing THC *might* be able to be exported and imported. The UK is the Next Big Thing in po...
Read ArticleHoney containing THC *might* be able to be exported and imported. The UK is the Next Big Thing in po...
Read Article
Open an account with an online broker of your choice. If you do not have an existing broker, consider Vested Equities' A$9.50 flat fee platform.
Sign up now »Place your order however you wish. If you need advice on buying or selling, you should seek the assistance of a full service financial adviser experienced in small cap equities.
